|
|
|
|
|
|
|
|
|
|
Access : A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea : British Journal of Cancer
Conclusion:
AGI004 demonstrated
effectiveness in reducing chemotherapy-associated diarrhoea, with
results suggesting response across multiple measurements of diarrhoea.
Treatment was well tolerated with no drug-related adverse events.
Further evaluation of this agent in the management of CID is warranted.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.